Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Mee-Kyoung Kim  (Kim MK) 3 Articles
Response: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52)
Sunghwan Suh, Gi Hyeon Seo, Chang Hee Jung, Mee-Kyoung Kim, Sang-Man Jin, You-Cheol Hwang, Byung-Wan Lee, Jae Hyeon Kim
Diabetes Metab J. 2015;39(4):350-351.   Published online August 17, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.4.350
  • 3,220 View
  • 29 Download
PDFPubReader   
Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database
Sunghwan Suh, Gi Hyeon Seo, Chang Hee Jung, Mee-Kyoung Kim, Sang-Man Jin, You-Cheol Hwang, Byung-Wan Lee, Jae Hyeon Kim
Diabetes Metab J. 2015;39(3):247-252.   Published online April 22, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.3.247
  • 3,971 View
  • 35 Download
  • 21 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   
Background

We assessed the association of dipeptidyl peptidase 4 inhibitors (DPP4i) with hospitalization for heart failure (HF) using the Korean Health Insurance claims database.

Methods

We collected data on newly prescribed sitagliptin, vildagliptin, and pioglitazone between January 1, 2009 and December 31, 2012 (mean follow-up of 336.8 days) to 935,519 patients with diabetes (518,614 males and 416,905 females) aged 40 to 79 years (mean age of 59.4 years).

Results

During the study, 998 patients were hospitalized for primary HF (115.7 per 100,000 patient-years). The incidence rate of hospitalization for HF was 117.7 per 100,000 per patient-years among patients on pioglitazone, 105.7 for sitagliptin, and 135.8 for vildagliptin. The hospitalization rate for HF was greatest in the first 30 days after starting the medication, which corresponded to a significantly higher incidence at days 0 to 30 compared with days 31 to 360 for all three drugs. The hazard ratios were 1.85 (pioglitazone), 2.00 (sitagliptin), and 1.79 (vildagliptin). The incidence of hospitalization for HF did not differ between the drugs for any time period.

Conclusion

This study showed an increase in hospitalization for HF in the initial 30 days of the DPP4i and pioglitazone compared with the subsequent follow-up period. However, the differences between the drugs were not significant.

Citations

Citations to this article as recorded by  
  • Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes
    Jui Wang, Hon-Yen Wu, Kuo-Liong Chien
    Diabetes & Metabolism.2022; 48(3): 101299.     CrossRef
  • Changing Fields-Diabetes Medications Invading the Cardiovascular Space
    Lauren D. Breite, Mackenzie Steck, Brandon Tate Cutshall, Samarth P. Shah, Brandon E. Cave
    Current Problems in Cardiology.2021; 46(3): 100736.     CrossRef
  • Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2
    Srikanth Yandrapalli, Aaqib Malik, Adam Horblitt, Gayatri Pemmasani, Wilbert S. Aronow, William H. Frishman
    Cardiology in Review.2020; 28(5): 219.     CrossRef
  • Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
    Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang, Feng Jiang
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
    Kyoung Jin Kim, Jimi Choi, Juneyoung Lee, Jae Hyun Bae, Jee Hyun An, Hee Young Kim, Hye Jin Yoo, Ji A. Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim, Nam Hoon Kim
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
    Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, Jinhee Lee, Hansol Choi, Hyeon Chang Kim, Dae Jung Kim
    Korean Circulation Journal.2018; 48(5): 395.     CrossRef
  • Worsening Heart Failure During the Use of DPP-4 Inhibitors
    Milton Packer
    JACC: Heart Failure.2018; 6(6): 445.     CrossRef
  • Resistance exercise improves cardiac function and mitochondrial efficiency in diabetic rat hearts
    Tae Hee Ko, Jubert C. Marquez, Hyoung Kyu Kim, Seung Hun Jeong, SungRyul Lee, Jae Boum Youm, In Sung Song, Dae Yun Seo, Hye Jin Kim, Du Nam Won, Kyoung Im Cho, Mun Gi Choi, Byoung Doo Rhee, Kyung Soo Ko, Nari Kim, Jong Chul Won, Jin Han
    Pflügers Archiv - European Journal of Physiology.2018; 470(2): 263.     CrossRef
  • Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?
    Milton Packer
    Circulation Research.2018; 122(7): 928.     CrossRef
  • Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes
    Hyouk-Jun Chin, Jin Hyun Nam, Eui-Kyung Lee, Ju-Young Shin
    Medicine.2017; 96(25): e7213.     CrossRef
  • Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction
    Nattayaporn Apaijai, Tharnwimol Inthachai, Suree Lekawanvijit, Siriporn C Chattipakorn, Nipon Chattipakorn
    Journal of Endocrinology.2016; 229(3): 245.     CrossRef
  • The current role of thiazolidinediones in diabetes management
    Christos V. Rizos, Anastazia Kei, Moses S. Elisaf
    Archives of Toxicology.2016; 90(8): 1861.     CrossRef
  • Alternative Interventions to Prevent Oxidative Damage following Ischemia/Reperfusion
    Simón Quetzalcoatl Rodríguez-Lara, Ernesto German Cardona-Muñoz, Ernesto Javier Ramírez-Lizardo, Sylvia Elena Totsuka-Sutto, Araceli Castillo-Romero, Teresa Arcelia García-Cobián, Leonel García-Benavides
    Oxidative Medicine and Cellular Longevity.2016; 2016: 1.     CrossRef
  • Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors
    Teresa Vanessa Fiorentino, Giorgio Sesti
    Endocrine.2016; 53(2): 373.     CrossRef
  • Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J2015;39:247-52)
    Dae Ho Lee
    Diabetes & Metabolism Journal.2015; 39(4): 348.     CrossRef
  • Response: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J2015;39:247-52)
    Sunghwan Suh, Gi Hyeon Seo, Chang Hee Jung, Mee-Kyoung Kim, Sang-Man Jin, You-Cheol Hwang, Byung-Wan Lee, Jae Hyeon Kim
    Diabetes & Metabolism Journal.2015; 39(4): 350.     CrossRef
  • Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
    Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Trynke Hoekstra, Mark H H Kramer, Indra C Pieters, Djuna L Cahen, Michaela Diamant, Daniël H van Raalte
    BMJ Open.2015; 5(11): e009579.     CrossRef
  • Dipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?
    Yong-ho Lee
    Diabetes & Metabolism Journal.2015; 39(3): 204.     CrossRef
Influence of Visceral Adiposity on Cardiovascular Autonomic Neuropathy in Patients with Type 2 Diabetes Mellitus
Eun-Hee Jang, Na-Young Kim, Yong-Moon Park, Mee-Kyoung Kim, Ki Hyun Baek, Ki-Ho Song, Kwang Woo Lee, Hyuk-Sang Kwon
Diabetes Metab J. 2012;36(4):285-292.   Published online August 20, 2012
DOI: https://doi.org/10.4093/dmj.2012.36.4.285
  • 3,558 View
  • 33 Download
  • 5 Crossref
AbstractAbstract PDFPubReader   
Background

The aim of this study was to investigate the influences of visceral adiposity on cardiovascular autonomic neuropathy (CAN) in patients with type 2 diabetes mellitus.

Methods

Two hundred eleven patients with type 2 diabetes participated in this study. Anthropometric and metabolic parameters were measured, and the visceral fat area was assessed using computed tomography. CAN was diagnosed using a cardiovascular reflex test. We analyzed the correlation between the visceral fat area and each parameter in this test.

Results

The mean age, body mass index (BMI), and duration of diabetes of the study population were 60±14 years (mean±standard deviation), 25.1±4.2 kg/m2, and 12.3±8.9 years, respectively. The visceral fat area showed positive correlations with age, BMI, waist circumference, and subcutaneous fat area. There was no statistically significant difference in the cardiovascular reflex test outcome between genders. Univariate linear regression analysis showed that an increased visceral fat area diminished good heart rate response to a Valsalva maneuver (R2=4.9%, P=0.013 in an unadjusted model), but only in women. This statistical association was preserved after adjusting for age and BMI (R2=9.8%, P=0.0072).

Conclusion

The results of this study suggest that visceral adiposity contributes to an autonomic imbalance to some degree, as demonstrated by the impaired cardiovascular reflex test among women with type 2 diabetes.

Citations

Citations to this article as recorded by  
  • Excessive generalized and visceral adiposity is associated with a higher prevalence of diabetic retinopathy in Caucasian patients with type 2 diabetes
    Andrea Tumminia, Agostino Milluzzo, Nunzia Carrubba, Federica Vinciguerra, Roberto Baratta, Lucia Frittitta
    Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(3): 763.     CrossRef
  • Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus
    Niki Katsiki, Panagiotis Anagnostis, Kalliopi Kotsa, Dimitrios G. Goulis, Dimitri P. Mikhailidis
    Current Pharmaceutical Design.2019; 25(18): 2051.     CrossRef
  • Morphologic Comparison of Peripheral Nerves in Adipocyte Tissue from db/db Diabetic versus Normal Mice
    Kyung Ae Lee, Na Young Lee, Tae Sun Park, Heung Yong Jin
    Diabetes & Metabolism Journal.2018; 42(2): 169.     CrossRef
  • Gender differences in the perception of difficulty of self-management in patients with diabetes mellitus: a mixed-methods approach
    Hideyo Tsutsui, Kyoko Nomura, Masataka Kusunoki, Tetsuya Ishiguro, Takayoshi Ohkubo, Yoshiharu Oshida
    Diabetology International.2016; 7(3): 289.     CrossRef
  • Contribution of subcutaneous abdominal fat on ultrasonography to carotid atherosclerosis in patients with type 2 diabetes mellitus
    Chan-Hee Jung, Bo-Yeon Kim, Kyu-Jin Kim, Sang-Hee Jung, Chul-Hee Kim, Sung-Koo Kang, Ji-Oh Mok
    Cardiovascular Diabetology.2014;[Epub]     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal